Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Marchaim

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Microbiology|March 7, 2014
Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing methodDror Marchaim, Jason M Pogue, Oran Tzuman, et al.
American Journal of Infection Control|January 31, 2012
The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilitiesDror Marchaim, Teena Chopra, Christopher Bogan, et al.
Infection Control and Hospital Epidemiology|March 19, 2021
A "resistance calculator": Simple stewardship intervention for refining empiric practices of antimicrobials in acute-care hospitalsShani Zilberman-Itskovich, Nathan Strul, Khalil Chedid, et al.
Antimicrobial Agents and Chemotherapy|February 23, 2012
Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremiaKayoko Hayakawa, Dror Marchaim, Emily T Martin, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2013
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical CenterKayoko Hayakawa, Sureka Gattu, Dror Marchaim, et al.
NEJM Evidence|August 4, 2023
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant OrganismsKeith S Kaye, Dror Marchaim, Visanu Thamlikitkul, et al.
Genome Medicine|February 14, 2023
Genomic analysis of the international high-risk clonal lineage Klebsiella pneumoniae sequence type 395Elvira R Shaidullina, Michael Schwabe, Thomas Rohde, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 6, 2026
The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME TrialJason M Pogue, Michael J Rybak, Jacinda C Abdul-Mutakabbir, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control studyKayoko Hayakawa, Dror Marchaim, Mohan Palla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2025
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative PathogensMariya Huralska, Jason M Pogue, Michael Rybak, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Microbiology|March 7, 2014
Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing methodDror Marchaim, Jason M Pogue, Oran Tzuman, et al.
American Journal of Infection Control|January 31, 2012
The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilitiesDror Marchaim, Teena Chopra, Christopher Bogan, et al.
Infection Control and Hospital Epidemiology|March 19, 2021
A "resistance calculator": Simple stewardship intervention for refining empiric practices of antimicrobials in acute-care hospitalsShani Zilberman-Itskovich, Nathan Strul, Khalil Chedid, et al.
Antimicrobial Agents and Chemotherapy|February 23, 2012
Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremiaKayoko Hayakawa, Dror Marchaim, Emily T Martin, et al.
Antimicrobial Agents and Chemotherapy|June 12, 2013
Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical CenterKayoko Hayakawa, Sureka Gattu, Dror Marchaim, et al.
NEJM Evidence|August 4, 2023
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant OrganismsKeith S Kaye, Dror Marchaim, Visanu Thamlikitkul, et al.
Genome Medicine|February 14, 2023
Genomic analysis of the international high-risk clonal lineage Klebsiella pneumoniae sequence type 395Elvira R Shaidullina, Michael Schwabe, Thomas Rohde, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 6, 2026
The Impact of Colistin MIC on Clinical Failure and Mortality: Insights from the OVERCOME TrialJason M Pogue, Michael J Rybak, Jacinda C Abdul-Mutakabbir, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Epidemiology of vancomycin-resistant Enterococcus faecalis: a case-case-control studyKayoko Hayakawa, Dror Marchaim, Mohan Palla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2025
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of Patients With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative PathogensMariya Huralska, Jason M Pogue, Michael Rybak, et al.
Pageof 11